Introduction
The pharmaceutical industry stands at a turning point. Value-based care (VBC) is no longer a distant policy concept — it is actively reshaping how drugs are priced, contracted, and delivered. Speaking live from the Asembia AXS26 Summit, Hinal Sharma outlined why this shift will define the pharma landscape over the next several years. Consequently, manufacturers, payers, and providers must adapt quickly or risk falling behind.
What Is Value-Based Care in Pharma?
Shifting from Volume to Outcomes
Value-based care moves the healthcare system away from fee-for-service models. Instead of paying for the number of prescriptions dispensed or procedures performed, payers reimburse based on patient outcomes. For pharma, this means that a drug’s real-world effectiveness — not just its clinical trial data — determines its financial value.
This shift places a new burden on manufacturers. They must now demonstrate that their therapies work in everyday patient populations, not just controlled settings. Moreover, they must build the data infrastructure to prove it.
Why Pharma Can No Longer Ignore VBC
Healthcare budgets are under increasing strain. Payers are demanding more accountability from drug makers. Furthermore, CMS and other regulatory bodies are pushing outcome-linked reimbursement frameworks across Medicare and Medicaid programs. Together, these pressures make value-based care a strategic necessity, not merely an ethical preference.
How Outcome-Based Contracts Are Changing Pricing
Outcome-Based Contracting (OBC) Explained
Outcome-based contracting is one of the most prominent VBC models taking hold in pharma. Under OBC, manufacturers and payers enter risk-sharing agreements where reimbursement levels are tied directly to treatment outcomes. If a drug performs as expected, the manufacturer receives full payment. If it underperforms, rebates or reduced payments apply.
This model benefits payers by reducing financial risk. It also motivates manufacturers to invest in drugs with strong real-world evidence. However, OBC requires robust data sharing and clear, mutually agreed-upon outcome metrics.
Indication-Based Management (IBM)
Indication-based management is another emerging model. Under IBM, the same drug can carry different price points depending on the specific condition it treats. This approach allows pharma companies to price therapies more accurately according to the value they deliver in each indication, rather than applying a single uniform price across all uses.
The Role of Technology and Real-World Data
Data as a Competitive Advantage
Technology is the backbone of value-based care. Real-time patient data, electronic health records, and population health analytics now give manufacturers the tools to track drug performance at scale. Additionally, AI-powered platforms help identify patient subgroups most likely to benefit from a given therapy, improving both clinical outcomes and commercial positioning.
AI’s Growing Role in Pharma VBC
Artificial intelligence is accelerating this transition. Pharma companies already use AI to screen drug interactions, design new molecules, and detect disease biomarkers. As AI capabilities mature, it will play an even larger role in predicting patient adherence, optimizing dosing protocols, and generating real-world evidence to support value-based contracts.
Key Challenges Pharma Must Overcome
Despite the momentum behind VBC, significant barriers remain. First, data standardization is inconsistent across health systems, making outcome measurement difficult. Second, negotiating mutually acceptable metrics between payers and manufacturers is complex and time-consuming. Third, smaller manufacturers may lack the infrastructure to participate meaningfully in outcome-linked contracts.
Furthermore, regulatory frameworks are still evolving. Therefore, pharma companies must invest in both policy engagement and internal capabilities simultaneously to stay ahead.
What the Future Holds for Pharma
A More Accountable Industry
Value-based care will ultimately push pharma toward greater transparency. Manufacturers that proactively build real-world evidence programs will gain significant advantages in contract negotiations. Those that resist this shift will face growing payer skepticism and formulary exclusions.
Patient-Centered Innovation
Equally important, VBC aligns pharma innovation with patient needs. As personalized medicine expands, value-based models will reward therapies that deliver meaningful outcomes for specific patient populations. This alignment drives both better science and more sustainable commercial models.
Conclusion
Value-based care is not a future trend — it is today’s reality. Pharma companies that embrace outcome-based contracting, invest in real-world data capabilities, and engage proactively with payers will be positioned to lead. Meanwhile, those that cling to volume-based thinking will struggle in an increasingly outcome-driven market. The message from Asembia AXS26 is clear: the industry must adapt now.
